Bio-X


Showing 41-60 of 69 Results

  • Miriam B. Goodman

    Miriam B. Goodman

    Mrs. George A. Winzer Professor of Cell Biology

    Current Research and Scholarly InterestsWe study the molecular events that give rise to the sensation of touch and temperature in C. elegans. To do this, we use a combination of quantitative behavioral analysis, genetics, in vivo electrophysiology, and heterologous expression of ion channels. We also collaborate with Pruitt's group in Mechanical Engineering to develop and fabricate novel devices for the study of sensory transduction.

  • Stuart Goodman, MD, PhD

    Stuart Goodman, MD, PhD

    The Robert L. and Mary Ellenburg Professor of Surgery and Professor, by courtesy, of Bioengineering

    Current Research and Scholarly InterestsAs an academic orthopaedic surgeon, my interests center on adult reconstructive surgery, arthritis surgery, joint replacement, biomaterials, biocompatibility, tissue engineering, mesenchymal stem cells. Collaborative clinical, applied and basic research studies are ongoing.

  • Kenneth Goodson

    Kenneth Goodson

    Senior Associate Dean for Faculty and Academic Affairs, Davies Family Provostial Professor, and Professor, by courtesy, of Materials Science and Engineering

    Current Research and Scholarly InterestsProf. Goodson’s Nanoheat Lab studies heat transfer in electronic nanostructures, microfluidic heat sinks, and packaging, focussing on basic transport physics and practical impact for industry. We work closely with companies on novel cooling and packaging strategies for power devices, portables, ASICs, & data centers. At present, sponsors and collaborators include ARPA-E, the NSF POETS Center, SRC ASCENT, Google, Intel, Toyota, Ford, among others.

  • William Rowland Goodyer, MD/PhD

    William Rowland Goodyer, MD/PhD

    Assistant Professor of Pediatrics (Cardiology)

    BioDr. Goodyer is a physician scientist who specializes in Pediatric Cardiology and Electrophysiology. Will graduated from McGill University (Montreal, Canada) with a BSc in Biology prior to completing his graduate studies at Stanford University in the Medical Scientist Training Program (MSTP). He subsequently completed residency training in Pediatrics at Boston Children’s Hospital before returning to Stanford to complete a fellowship in Pediatric Cardiology and advanced fellowship in Pediatric Electrophysiology. He additionally performed a postdoctoral fellowship in the Sean Wu laboratory at the Stanford Cardiovascular Institute where he developed the first comprehensive single-cell gene atlas of the entire murine cardiac conduction system (CCS) as well as pioneered the generation of optical imaging agents for the real-time visualization of the CCS to help prevent accidental surgical damage during heart surgeries. Will's lab (www.goodyerlab.com) focuses on basic science advances aimed at the improved diagnosis and treatment of cardiac arrhythmias.

  • Deborah M Gordon

    Deborah M Gordon

    Professor of Biology

    Current Research and Scholarly InterestsProfessor Deborah M Gordon studies the evolutionary ecology of collective behavior. Ant colonies operate without central control, using local interactions to regulate colony behavior.

  • Jorg Goronzy

    Jorg Goronzy

    Professor of Medicine (Immunology and Rheumatology), Emeritus

    Current Research and Scholarly InterestsT cell homeostasis and function with age

  • Ian Gotlib

    Ian Gotlib

    David Starr Jordan Professor

    Current Research and Scholarly InterestsCurrent interests include social, cognitive, and biological factors in affective disorders; neural and cognitive processing of emotional stimuli and reward by depressed persons; behavioral activation and anhedonia in depression; social, emotional, and biological risk factors for depression in children.

  • Or Gozani

    Or Gozani

    Dr. Morris Herzstein Professor

    Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.

  • Edward Graves

    Edward Graves

    Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)

    Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.

  • Nathanael S. Gray

    Nathanael S. Gray

    Krishnan-Shah Family Professor

    BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
    Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
    In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
    In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
    These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023.

  • Henry T. (Hank) Greely

    Henry T. (Hank) Greely

    Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics

    Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.

  • Sherril L. Green, DVM, PhD

    Sherril L. Green, DVM, PhD

    Professor of Comparative Medicine, Emerita

    Current Research and Scholarly InterestsResearch Interests: Xenopus laevis. Husbandry, biology, infectious and parasitic diseases of laboratory Xenopus laevis. Large animal models of disease.

  • Tamar Green

    Tamar Green

    Assistant Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences)

    Current Research and Scholarly InterestsThe Brain Imaging, Development, and Genetic (BRIDGE) Lab focuses on disorders associated with child development, such as attention deficits, hyperactivity, and autism spectrum disorders. we aim to uncover biological principles of how genetic variation and its associated downstream pathways affect children's neurodevelopmental disorders.

  • Harry B Greenberg

    Harry B Greenberg

    Joseph D. Grant Professor in the School of Medicine, Emeritus

    Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.

  • Peter Greenberg

    Peter Greenberg

    Professor of Medicine (Hematology), Emeritus

    Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.

  • William Greenleaf

    William Greenleaf

    Professor of Genetics

    Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.

  • Michael Greicius, MD, MPH

    Michael Greicius, MD, MPH

    Iqbal Farrukh and Asad Jamal Professor and Professor, by courtesy, of Psychiatry and Behavioral Sciences (Administrative and Academic Special Programs)

    Current Research and Scholarly InterestsAs the Medical Director of the Stanford Center for Memory Disorders and Principal Investigator of the Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) Cohort, Dr. Greicius' research focuses on elucidating the neurobiologic underpinnings of AD. His lab combines cutting edge brain imaging, "deep" phenotyping, and whole-genome sequencing of human subjects to identify novel pathways involved in AD pathogenesis. The goal of his work is to develop effective treatment for AD patients.

  • Kalanit Grill-Spector

    Kalanit Grill-Spector

    Susan S. and William H. Hindle Professor in the School of Humanities and Sciences

    Current Research and Scholarly InterestsFor humans, recognition is a natural, effortless skill that occurs within a few hundreds of milliseconds, yet it is one of the least understood aspects of visual perception. Our research utilizes functional imaging (fMRI),diffusion weighted imaging (DWI), computational techniques, and behavioral methods to investigate the neural mechanisms underlying visual recognition in humans. We also examine the development of these mechanisms from childhood to adulthood as well as between populations.

  • Nicolas Grillet, PhD

    Nicolas Grillet, PhD

    Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)

    Current Research and Scholarly InterestsWe are interested in identifying the genes leading to Hearing and Vestibular impairments, and understanding their function at the molecular level.
    We have a special focus on how the Hair Cells are able to detect mechanical stimulation.